ImpediMed Director Increases Shareholding in Strategic Move
Impedimed Limited (AU:IPD) announced that director Andrew Grant increased his shareholding by acquiring 98,347 ordinary shares, using 15% of his director fees for Q3 2025. This strategic move aligns his interests with the company's performance, potentially boosting stakeholder confidence. The latest analyst rating for AU:IPD is a Buy with a price target of A$0.13. ImpediMed specializes in non-invasive medical devices, focusing on fluid status and tissue composition measurement.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Impedimed Limited ( (AU:IPD) ) has provided an update.
ImpediMed Limited announced a change in the director’s interest notice, revealing that Mr. Andrew Grant, a director, has increased his holdings in the company by acquiring 98,347 ordinary shares. This acquisition was made in lieu of 15% of his director fees for the quarter ended 30 September 2025, reflecting a strategic move to align interests with the company’s performance. This development may indicate confidence in the company’s future prospects and could potentially impact stakeholder perceptions positively.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.13 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
ImpediMed Limited operates in the medical technology industry, specializing in non-invasive medical devices. The company focuses on providing solutions for the measurement of fluid status and tissue composition, primarily through bioimpedance spectroscopy technology.
Average Trading Volume: 1,808,782
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$77.37M
For a thorough assessment of IPD stock, go to TipRanks’ Stock Analysis page.
